United State Neuromyelitis Optica Spectrum Disorder Market
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Intravenous
1.2.3 Oral
1.2.4 Subcutaneous
1.2.5 Others
1.3 Market by Application
1.3.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Perspective (2016-2027)
2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Growth Trends by Regions
2.2.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Share by Regions (2016-2021)
2.2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027)
2.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Industry Dynamic
2.3.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
2.3.2 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
2.3.3 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
2.3.4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue
3.1.1 Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Revenue (2016-2021)
3.1.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Players (2016-2021)
3.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue
3.4 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio
3.4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
3.5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Key Players Head office and Area Served
3.6 Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
3.7 Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Type
4.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Type (2016-2021)
4.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027)
5 Neuromyelitis Optica Spectrum Disorder (NMOSD) Breakdown Data by Application
5.1 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Historic Market Size by Application (2016-2021)
5.2 Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
6.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
6.2.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
6.2.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
6.2.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
6.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
6.3.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
6.3.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
6.3.3 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
6.4 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
6.4.1 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
6.4.2 North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
7.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
7.2.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
7.2.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
7.2.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
7.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
7.3.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
7.3.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
7.3.3 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
7.4 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
7.4.1 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
7.4.2 Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
8.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
8.2.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
8.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
8.3.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
8.4 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region
8.4.1 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
9.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
9.2.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
9.2.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
9.2.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
9.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
9.3.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
9.3.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
9.3.3 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
9.4 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
9.4.1 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
9.4.2 Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (2016-2027)
10.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type
10.2.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2027)
10.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application
10.3.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2027)
10.4 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country
10.4.1 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche Ltd
11.1.1 F. Hoffmann-La Roche Ltd Company Details
11.1.2 F. Hoffmann-La Roche Ltd Business Overview
11.1.3 F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.1.4 F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.1.5 F. Hoffmann-La Roche Ltd Recent Development
11.2 Alexion Pharmaceuticals
11.2.1 Alexion Pharmaceuticals Company Details
11.2.2 Alexion Pharmaceuticals Business Overview
11.2.3 Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.2.4 Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.2.5 Alexion Pharmaceuticals Recent Development
11.3 RemeGen
11.3.1 RemeGen Company Details
11.3.2 RemeGen Business Overview
11.3.3 RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.3.4 RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.3.5 RemeGen Recent Development
11.4 Nihon Pharmaceutical
11.4.1 Nihon Pharmaceutical Company Details
11.4.2 Nihon Pharmaceutical Business Overview
11.4.3 Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.4.4 Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.4.5 Nihon Pharmaceutical Recent Development
11.5 Harbour BioMed
11.5.1 Harbour BioMed Company Details
11.5.2 Harbour BioMed Business Overview
11.5.3 Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.5.4 Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.5.5 Harbour BioMed Recent Development
11.6 Lundbeck
11.6.1 Lundbeck Company Details
11.6.2 Lundbeck Business Overview
11.6.3 Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.6.4 Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.6.5 Lundbeck Recent Development
11.7 Bionure
11.7.1 Bionure Company Details
11.7.2 Bionure Business Overview
11.7.3 Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.7.4 Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.7.5 Bionure Recent Development
11.8 Opexa Therapeutics
11.8.1 Opexa Therapeutics Company Details
11.8.2 Opexa Therapeutics Business Overview
11.8.3 Opexa Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.8.4 Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.8.5 Opexa Therapeutics Recent Development
11.9 TG Therapeutics
11.9.1 TG Therapeutics Company Details
11.9.2 TG Therapeutics Business Overview
11.9.3 TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.9.4 TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.9.5 TG Therapeutics Recent Development
11.10 Bio-Thera Solutions
11.10.1 Bio-Thera Solutions Company Details
11.10.2 Bio-Thera Solutions Business Overview
11.10.3 Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.10.4 Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.10.5 Bio-Thera Solutions Recent Development
11.11 Boston Pharmaceuticals
11.11.1 Boston Pharmaceuticals Company Details
11.11.2 Boston Pharmaceuticals Business Overview
11.11.3 Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.11.4 Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.11.5 Boston Pharmaceuticals Recent Development
11.12 Cour Pharmaceutical
11.12.1 Cour Pharmaceutical Company Details
11.12.2 Cour Pharmaceutical Business Overview
11.12.3 Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Introduction
11.12.4 Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
11.12.5 Cour Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Intravenous
Table 3. Key Players of Oral
Table 4. Key Players of Subcutaneous
Table 5. Key Players of Others
Table 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2016-2021)
Table 10. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
Table 12. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Trends
Table 13. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Drivers
Table 14. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Challenges
Table 15. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Restraints
Table 16. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players (2016-2021)
Table 18. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020)
Table 19. Ranking of Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Neuromyelitis Optica Spectrum Disorder (NMOSD) Product Solution and Service
Table 23. Date of Enter into Neuromyelitis Optica Spectrum Disorder (NMOSD) Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
Table 27. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2016-2021)
Table 31. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size by Country (2022-2027) & (US$ Million)
Table 63. F. Hoffmann-La Roche Ltd Company Details
Table 64. F. Hoffmann-La Roche Ltd Business Overview
Table 65. F. Hoffmann-La Roche Ltd Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 66. F. Hoffmann-La Roche Ltd Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 67. F. Hoffmann-La Roche Ltd Recent Development
Table 68. Alexion Pharmaceuticals Company Details
Table 69. Alexion Pharmaceuticals Business Overview
Table 70. Alexion Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 71. Alexion Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 72. Alexion Pharmaceuticals Recent Development
Table 73. RemeGen Company Details
Table 74. RemeGen Business Overview
Table 75. RemeGen Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 76. RemeGen Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 77. RemeGen Recent Development
Table 78. Nihon Pharmaceutical Company Details
Table 79. Nihon Pharmaceutical Business Overview
Table 80. Nihon Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 81. Nihon Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 82. Nihon Pharmaceutical Recent Development
Table 83. Harbour BioMed Company Details
Table 84. Harbour BioMed Business Overview
Table 85. Harbour BioMed Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 86. Harbour BioMed Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 87. Harbour BioMed Recent Development
Table 88. Lundbeck Company Details
Table 89. Lundbeck Business Overview
Table 90. Lundbeck Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 91. Lundbeck Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 92. Lundbeck Recent Development
Table 93. Bionure Company Details
Table 94. Bionure Business Overview
Table 95. Bionure Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 96. Bionure Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 97. Bionure Recent Development
Table 98. Opexa Therapeutics Company Details
Table 99. Opexa Therapeutics Business Overview
Table 100. Opexa Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 101. Opexa Therapeutics Recent Development
Table 102. TG Therapeutics Company Details
Table 103. TG Therapeutics Business Overview
Table 104. TG Therapeutics Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 105. TG Therapeutics Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 106. TG Therapeutics Recent Development
Table 107. Bio-Thera Solutions Company Details
Table 108. Bio-Thera Solutions Business Overview
Table 109. Bio-Thera Solutions Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 110. Bio-Thera Solutions Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 111. Bio-Thera Solutions Recent Development
Table 112. Boston Pharmaceuticals Company Details
Table 113. Boston Pharmaceuticals Business Overview
Table 114. Boston Pharmaceuticals Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 115. Boston Pharmaceuticals Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 116. Boston Pharmaceuticals Recent Development
Table 117. Cour Pharmaceutical Company Details
Table 118. Cour Pharmaceutical Business Overview
Table 119. Cour Pharmaceutical Neuromyelitis Optica Spectrum Disorder (NMOSD) Product
Table 120. Cour Pharmaceutical Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021) & (US$ Million)
Table 121. Cour Pharmaceutical Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type: 2020 VS 2027
Figure 2. Intravenous Features
Figure 3. Oral Features
Figure 4. Subcutaneous Features
Figure 5. Others Features
Figure 6. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application: 2020 VS 2027
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Others Case Studies
Figure 10. Neuromyelitis Optica Spectrum Disorder (NMOSD) Report Years Considered
Figure 11. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions: 2020 VS 2027
Figure 14. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Regions (2022-2027)
Figure 15. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Players in 2020
Figure 16. Global Top Neuromyelitis Optica Spectrum Disorder (NMOSD) Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromyelitis Optica Spectrum Disorder (NMOSD) as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue in 2020
Figure 18. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2016-2021)
Figure 19. Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Revenue Market Share by Type (2022-2027)
Figure 20. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 22. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 23. North America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 24. United States Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 28. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 29. Europe Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 30. Germany Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Region (2016-2027)
Figure 40. China Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 48. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 49. Latin America Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 50. Mexico Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share by Country (2016-2027)
Figure 56. Turkey Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 60. Alexion Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 61. RemeGen Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 62. Nihon Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 63. Harbour BioMed Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 64. Lundbeck Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 65. Bionure Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 66. Opexa Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 67. TG Therapeutics Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 68. Bio-Thera Solutions Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 69. Boston Pharmaceuticals Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 70. Cour Pharmaceutical Revenue Growth Rate in Neuromyelitis Optica Spectrum Disorder (NMOSD) Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
